Literature DB >> 26290636

Endozepine-4 levels are increased in hepatic coma.

Giulia Malaguarnera1, Marco Vacante1, Filippo Drago1, Gaetano Bertino1, Massimo Motta1, Maria Giordano1, Michele Malaguarnera1.   

Abstract

AIM: To evaluate the serum levels of endozepine-4, their relation with ammonia serum levels, the grading of coma and the severity of cirrhosis, in patients with hepatic coma.
METHODS: In this study we included 20 subjects with Hepatic coma, 20 subjects with minimal hepatic encephalopathy (MHE) and 20 subjects control. All subjects underwent blood analysis, Child Pugh and Model for End - stage liver disease (MELD) assessment, endozepine-4 analysis.
RESULTS: Subjects with hepatic coma showed significant difference in endozepine-4 (P < 0.001) and NH3 levels (P < 0.001) compared both to MHE and controls patients. Between NH3 and endozepine-4 we observed a significant correlation (P = 0.009; Pearson correlation 0.570). There was a significant correlation between endozepine-4 and MELD (P = 0.017; Pearson correlation = 0.529). In our study blood ammonia concentration was noted to be raised in patients with hepatic coma, with the highest ammonia levels being found in those who were comatose. We also found a high correlation between endozepine-4 and ammonia (P < 0.001). In patients with grade IV hepatic coma, endozepine levels were significantly higher compared to other groups.
CONCLUSION: This study suggests that an increased level of endozepine in subjects with higher levels of MELD was observed. In conclusion, data concerning involvement of the GABA-ergic system in HE coma could be explained by stage-specific alterations.

Entities:  

Keywords:  Cirrhosis, Benzodiazepine; Endozepine-4; Glutamate-related neurotoxicity which in turn may alter the γ-aminobutyric acid; Hepatic coma; Hepatic encephalopathy; Model for End - stage liver disease; Peripheral benzodiazepine receptor

Mesh:

Substances:

Year:  2015        PMID: 26290636      PMCID: PMC4533041          DOI: 10.3748/wjg.v21.i30.9103

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  47 in total

1.  Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study.

Authors:  Piero Amodio; Francesca Campagna; Stefania Olianas; Pamela Iannizzi; Daniela Mapelli; Marco Penzo; Paolo Angeli; Angelo Gatta
Journal:  J Hepatol       Date:  2008-06-02       Impact factor: 25.083

Review 2.  Molecular and functional properties of mitochondrial benzodiazepine receptors.

Authors:  K E Krueger
Journal:  Biochim Biophys Acta       Date:  1995-12-20

3.  Metabolism of the inhibitory neurotransmitter gamma-aminobutyric acid in a rabbit model of fulminant hepatic failure.

Authors:  P Ferenci; D Covell; D F Schafer; J G Waggoner; R Shrager; E A Jones
Journal:  Hepatology       Date:  1983 Jul-Aug       Impact factor: 17.425

Review 4.  Diagnosis and treatment of hepatic encephalopathy.

Authors:  A T Blei
Journal:  Baillieres Best Pract Res Clin Gastroenterol       Date:  2000-12

5.  Cerebral oedema and increased intracranial pressure in chronic liver disease.

Authors:  J P Donovan; D F Schafer; B W Shaw; M F Sorrell
Journal:  Lancet       Date:  1998-03-07       Impact factor: 79.321

Review 6.  Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives.

Authors:  Giulia Malaguarnera; Maria Giordano; Giuseppe Nunnari; Gaetano Bertino; Michele Malaguarnera
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

7.  A study of diazepam binding inhibitor (DBI) processing products in human cerebrospinal fluid and in postmortem human brain.

Authors:  P Guarneri; A Berkovich; A Guidotti; E Costa
Journal:  Neuropharmacology       Date:  1990-05       Impact factor: 5.250

8.  Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study.

Authors:  Mariano Malaguarnera; Corrado Risino; Lisa Cammalleri; Lucia Malaguarnera; Marinella Astuto; Ignazio Vecchio; Liborio Rampello
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-07       Impact factor: 2.566

9.  Diazepam binding inhibitor-like immunoreactivity(51-70): distribution in human brain, spinal cord and peripheral tissues.

Authors:  J A Ball; M A Ghatei; K Sekiya; T Krausz; S R Bloom
Journal:  Brain Res       Date:  1989-02-13       Impact factor: 3.252

10.  Isolation, characterization, and purification to homogeneity of an endogenous polypeptide with agonistic action on benzodiazepine receptors.

Authors:  A Guidotti; C M Forchetti; M G Corda; D Konkel; C D Bennett; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

View more
  8 in total

Review 1.  Hepatocellular carcinoma and the risk of occupational exposure.

Authors:  Venerando Rapisarda; Carla Loreto; Michele Malaguarnera; Annalisa Ardiri; Maria Proiti; Giuseppe Rigano; Evelise Frazzetto; Maria Irene Ruggeri; Giulia Malaguarnera; Nicoletta Bertino; Mariano Malaguarnera; Vito Emanuele Catania; Isidoro Di Carlo; Adriana Toro; Emanuele Bertino; Dario Mangano; Gaetano Bertino
Journal:  World J Hepatol       Date:  2016-05-08

Review 2.  Hyperammonemia in Hepatic Encephalopathy.

Authors:  A R Jayakumar; Michael D Norenberg
Journal:  J Clin Exp Hepatol       Date:  2018-06-20

3.  Wernicke encephalopathy in a patient with liver failure: Clinical case report.

Authors:  Pan Zhao; Yanling Zhao; Zhenman Wei; Jing Chen; Lilong Yan
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

4.  Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.

Authors:  Giulia Malaguarnera; Gaetano Bertino; Giuseppe Chisari; Massimo Motta; Michele Vecchio; Marco Vacante; Filippo Caraci; Carmela Greco; Filippo Drago; Giuseppe Nunnari; Michele Malaguarnera
Journal:  BMC Psychiatry       Date:  2016-11-15       Impact factor: 3.630

5.  Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance.

Authors:  Manuela Pennisi; Gaetano Bertino; Caterina Gagliano; Michele Malaguarnera; Rita Bella; Antonio Maria Borzì; Roberto Madeddu; Filippo Drago; Giulia Malaguarnera
Journal:  Nutrients       Date:  2017-08-18       Impact factor: 5.717

6.  Resveratrol in Patients with Minimal Hepatic Encephalopathy.

Authors:  Giulia Malaguarnera; Manuela Pennisi; Gaetano Bertino; Massimo Motta; Antonio Maria Borzì; Enzo Vicari; Rita Bella; Filippo Drago; Michele Malaguarnera
Journal:  Nutrients       Date:  2018-03-09       Impact factor: 5.717

7.  D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis.

Authors:  Michele Malaguarnera; Saverio Latteri; Gaetano Bertino; Roberto Madeddu; Vito Emanuele Catania; Giuseppe Currò; Antonio Maria Borzì; Filippo Drago; Giulia Malaguarnera
Journal:  Clin Exp Gastroenterol       Date:  2018-10-03

8.  Carnitine Serum Levels in Frail Older Subjects.

Authors:  Giulia Malaguarnera; Vito Emanuele Catania; Claudia Bonfiglio; Gaetano Bertino; Enzo Vicari; Michele Malaguarnera
Journal:  Nutrients       Date:  2020-12-19       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.